# Hims & Hers Stock After Q3 2026: Growth Paid to Drugmakers — InvestMoat Research

_Hims & Hers lifted monthly revenue per subscriber to $105 in Q3 2026, up from $85 in early 2025, but by our arithmetic gross profit per subscriber is still about $60, no higher than then. We think branded GLP-1 drugs moved the revenue, not the profit, and that leaves Hims a narrower moat than its 49% growth suggests._

_Published: November 15, 2026 · Last reviewed: November 15, 2026 · Canonical page: https://www.investmoat.com/research/hims-q3-and-the-subscriber-profit-that-did-not-grow_
_Tags: Earnings, GLP-1, Healthcare, Telehealth_
_Covers: HIMS, LLY, NVO_

## Summary

Hims & Hers reported 49% revenue growth for Q3 2026, and monthly revenue per subscriber reached $105, against $85 in Q1 2025. Gross margin fell to 57% from 73% over the same span, so gross profit per subscriber, by our arithmetic, is about $60 a month, slightly below early 2025 after a Q1 2026 low near $52. The added revenue came as Hims moved US weight loss to Novo Nordisk's branded drugs and bought Eucalyptus, which sells branded GLP-1s abroad at lower margins; Lilly's November 2026 deal adds its drugs at the same self-pay prices any patient pays. We read that as Hims distributing a product it doesn't price, and the test is whether gross profit per subscriber climbs in 2027 as the CFO expects margin declines to moderate.

## What would prove this wrong

We're wrong if Hims & Hers's gross profit per subscriber (quarterly gross profit divided by average subscribers, divided by three; about $60 in Q3 2026) reaches $66 or more in any quarter reported by August 2027, or if gross margin returns above 65% while monthly revenue per subscriber stays above $100.

_Status as of November 15, 2026: **holding**._

---

**We think Hims & Hers's Q3 2026 growth moved revenue, not profit.** The market reads 49% revenue growth and a second straight quarter of acceleration as the business recovering. By our arithmetic, each subscriber brings in about $105 a month now against $85 in early 2025, but Hims keeps about $60 of gross profit from them, no more than it did then. The new dollars come from branded GLP-1 drugs that Novo Nordisk prices, and soon Eli Lilly too, so in weight loss Hims earns a distributor's cut, and its growth rate overstates what the platform is gaining.

**Revenue per subscriber rose about a quarter from Q1 2025 to Q3 2026. Gross profit per subscriber dipped to about $52 in Q1 2026, the first quarter of the branded switch, and has climbed back to roughly where it started. The gap is drug cost: Novo's branded drugs in the US since March, and Eucalyptus, the lower-margin international business Hims bought in June.**

| Period | Monthly revenue per subscriber | Monthly gross profit per subscriber |
| --- | --- | --- |
| Q1 2025 | $85 | $62 |
| Q2 2025 | $76 | $58 |
| Q3 2025 | $81 | $60 |
| Q4 2025 | $83 | $60 |
| Q1 2026 | $80 | $52 |
| Q2 2026 | $92 | $59 |
| Q3 2026 | $105 | $60 |

Q1 2026: Branded switch starts.

Revenue per subscriber is the company's reported monthly revenue per average subscriber. Gross profit per subscriber is our arithmetic: quarterly gross profit divided by average subscribers, divided by three, rounded. Q1 2025 comes from the comparison column of the Q1 2026 release.

_Figures as of November 9, 2026. Source: [Hims & Hers Health, Inc. reports fourth quarter and full year 2025 financial results](https://www.businesswire.com/news/home/20260223564900/en/Hims-Hers-Health-Inc.-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results); [Hims & Hers Health, Inc. reports first quarter 2026 financial results (Form 8-K)](https://www.sec.gov/Archives/edgar/data/0001773751/000177375126000074/hims-20260331x8xkearningsr.htm); [Hims & Hers Health, Inc. reports second quarter 2026 financial results (Form 8-K)](https://www.sec.gov/Archives/edgar/data/0001773751/000177375126000161/hims-20260630x8xkearningsr.htm); [Hims & Hers Health, Inc. reports third quarter 2026 financial results (Form 8-K)](https://www.sec.gov/Archives/edgar/data/0001773751/000177375126000242/hims-20260930x8xkearningsr.htm)._

## Where the extra revenue went

Until early 2026, Hims's weight-loss business ran on compounded semaglutide made in its own pharmacies, a product it priced itself. Two deals replaced it with branded drugs priced by the companies that make them.

**The two deals behind the switch. A self-pay price is the cash price without insurance. Hims's March release gives no prices for the Novo drugs; Lilly's November release says Hims patients pay the same self-pay prices any patient can get.**

| Deal | Drugs on Hims | Price to the patient |
| --- | --- | --- |
| Novo Nordisk, March 9, 2026 | Wegovy pills and injections, Ozempic | Not disclosed |
| Eli Lilly, November 6, 2026 | Zepbound injection, Foundayo pill | Same cash price as anywhere: from $299 a month (Zepbound), $149 (Foundayo) |

_Figures as of November 6, 2026. Source: [Hims & Hers announces strategic shift for US weight loss business](https://www.businesswire.com/news/home/20260309674463/en/Hims-Hers-Announces-Strategic-Shift-for-US-Weight-Loss-Business); [Lilly and Hims & Hers expand access to FDA-approved Lilly medicines](https://investor.lilly.com/news-releases/news-release-details/lilly-and-hims-hers-expand-access-fda-approved-lilly-medicines)._

With Novo, Hims also agreed to stop advertising compounded GLP-1s and keep them only "on a limited scale", and Novo dismissed its patent lawsuit, without prejudice, so it could refile. With Lilly, Hims committed never to offer compounded copies of Lilly's drugs. The price column matters most for the moat. A patient pays Hims what they'd pay anywhere else, and the drugmaker sets that price. Hims can win the visit, the prescription and the delivery, but the product margin sits with the drugmaker. Lilly's drugs aren't in the chart yet; the deal was signed after the quarter closed.

**The quarter in the lines that bear on the moat. Hims also cut its 2026 adjusted EBITDA guide to $257-277 million from $275-325 million in August.**

| Measure | Q3 2025 | Q2 2026 | Q3 2026 |
| --- | --- | --- | --- |
| Revenue | $599M | $753M | $890M |
| Rest of world revenue | $55M | $131M | $233M |
| Of which Eucalyptus | None (bought June 2026) | Part quarter, not given | About $135M (per the CFO) |
| Subscribers, end of quarter | 2.47M | 2.89M | 2.79M |
| Gross margin | 74% | 64% | 57% |
| Marketing spend | $232M | $262M | $247M |

_Figures as of November 9, 2026. Source: [Hims & Hers Health, Inc. reports third quarter 2026 financial results (Form 8-K)](https://www.sec.gov/Archives/edgar/data/0001773751/000177375126000242/hims-20260930x8xkearningsr.htm); [Hims & Hers Health, Inc. reports second quarter 2026 financial results (Form 8-K)](https://www.sec.gov/Archives/edgar/data/0001773751/000177375126000161/hims-20260630x8xkearningsr.htm); [Hims & Hers Q3 2026 earnings call transcript](https://uk.investing.com/news/stock-market-news/earnings-call-transcript-hims--hers-misses-q3-2026-profit-view-shares-fall-93CH-4970016)._

Subscribers fell by about 100,000 from June. CFO Yemi Okupe gave two reasons on the [earnings call](https://uk.investing.com/news/stock-market-news/earnings-call-transcript-hims--hers-misses-q3-2026-profit-view-shares-fall-93CH-4970016): "measured marketing spend in our domestic weight loss specialty" and "brand migrations in our international markets". Marketing was down only about 6% from Q2. A US weight-loss customer who can get the same branded drug at the same price elsewhere has to be won with ads each time, and that is what a 6% trim exposed. Some of the drop is also patients on cheap compounded semaglutide leaving as Hims phased it out, which points the same way: the product they stayed for is gone.

## The case against us: it's Eucalyptus, and it's already turning

The strongest objection is that our chart blends two businesses. Eucalyptus, consolidated for its first full quarter, sells branded GLP-1s at low margins in Australia, the UK, Germany, Canada and Japan, and Okupe said on the call that it contributed about $135 million of the $233 million in rest-of-world revenue. He said "the scaling of branded weight loss products in our international business, which carry lower gross margins" drove most of the margin drop from Q2. US revenue grew 21%. Hims doesn't report gross margin by region, so the US business could still be earning more per subscriber than a year ago.

The chart itself also shows a recovery. Gross profit per subscriber rose about 15% from the Q1 2026 low, and marketing fell from 39% of revenue to 28% over the year, so gross profit after marketing per subscriber is a little higher than a year ago. CEO Andrew Dudum's case is that "in healthcare, whoever owns the customer relationship wins," backed by "more than 1 million square feet of pharmacy, lab, and compounding infrastructure." Okupe expects "gross margin declines to start to moderate as the pace of mix shifts towards international and weight loss specialty begins to moderate."

Our answer is that the recovery so far only returns Hims to its 2025 level while revenue per subscriber is a quarter higher, and that the US offers no separate evidence it is doing better. If the platform's pull is real, gross profit per subscriber should climb past its old range once Eucalyptus laps its first year in mid-2027. We've set the bar at $66 a month by August 2027; if Hims clears it, we're wrong.

## What it means for the stock

The framework still rates Hims's subscription bundle as a moat, and it doesn't score weight loss on its own; narrowing in that category is our reading. Weight loss, Hims's biggest growth driver, is now a resale business at the drugmaker's price, and the pricing power in it sits with [Eli Lilly](/stocks/lly) and [Novo Nordisk](/stocks/nvo). Our [Lilly Q3 piece](/research/lilly-q3-and-the-price-cut-the-margin-absorbed) argued Lilly could absorb its own GLP-1 price cuts; this quarter shows where a distributor lands. For a holder, that means valuing Hims on gross profit per subscriber, not revenue. The scorecard below sets the framework's live scores for all three side by side.

**Hims & Hers beside the two drugmakers whose GLP-1s it sells. Each score is the framework's 0-100 rating of moat, growth and valuation, live from the stock pages.**

| Ticker | Name | Moat | Growth | Valuation | Composite | Note |
| --- | --- | --- | --- | --- | --- | --- |
| [HIMS](https://www.investmoat.com/stocks/hims) | Hims & Hers Health | 54 | 73 | 88 | 71 | Resells branded GLP-1s at the makers' prices; Q3 2026 gross margin 57% |
| [LLY](https://www.investmoat.com/stocks/lly) | Eli Lilly and Company | 71 | 81 | 66 | 73 | Sets the self-pay price of Zepbound and Foundayo on Hims |
| [NVO](https://www.investmoat.com/stocks/nvo) | Novo Nordisk | 54 | 49 | 85 | 59 | Brought Wegovy and Ozempic to Hims in March 2026 |

_Valuation and composite above use each asset's static valuation score; the live site recomputes them against the current market price._

## Sources

1. [Hims & Hers Health, Inc. reports third quarter 2026 financial results (Form 8-K)](https://www.sec.gov/Archives/edgar/data/0001773751/000177375126000242/hims-20260930x8xkearningsr.htm) — Hims & Hers Health, Inc., November 9, 2026 (filing)
2. [Hims & Hers Health, Inc. reports second quarter 2026 financial results (Form 8-K)](https://www.sec.gov/Archives/edgar/data/0001773751/000177375126000161/hims-20260630x8xkearningsr.htm) — Hims & Hers Health, Inc., August 10, 2026 (filing)
3. [Hims & Hers Health, Inc. reports first quarter 2026 financial results (Form 8-K)](https://www.sec.gov/Archives/edgar/data/0001773751/000177375126000074/hims-20260331x8xkearningsr.htm) — Hims & Hers Health, Inc., May 11, 2026 (filing)
4. [Hims & Hers Health, Inc. reports fourth quarter and full year 2025 financial results](https://www.businesswire.com/news/home/20260223564900/en/Hims-Hers-Health-Inc.-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results) — Hims & Hers Health, Inc., February 23, 2026 (press-release)
5. [Hims & Hers Q3 2026 earnings call transcript](https://uk.investing.com/news/stock-market-news/earnings-call-transcript-hims--hers-misses-q3-2026-profit-view-shares-fall-93CH-4970016) — Investing.com, November 10, 2026 (transcript)
6. [Lilly and Hims & Hers expand access to FDA-approved Lilly medicines](https://investor.lilly.com/news-releases/news-release-details/lilly-and-hims-hers-expand-access-fda-approved-lilly-medicines) — Eli Lilly and Company, November 6, 2026 (press-release)
7. [Hims & Hers announces strategic shift for US weight loss business](https://www.businesswire.com/news/home/20260309674463/en/Hims-Hers-Announces-Strategic-Shift-for-US-Weight-Loss-Business) — Hims & Hers Health, Inc., March 9, 2026 (press-release)

---

Scores are computed deterministically from each asset's data file: composite = Moat^0.40 × Growth^0.30 × Valuation^0.30, scaled to 0–100.

Full analyses for every name above: https://www.investmoat.com/stocks. Site index for agents: https://www.investmoat.com/llms.txt

InvestMoat is an open-source research and education framework. Nothing here is financial advice.